公开(公告)号：KR101500654B1

公开(公告)日：2015-03-12

申请号：KR1020130121448

申请日：2013-10-11

Applicant: 한국과학기술연구원

Inventor： 이재욱 ,  함정엽 ,  정봉철 ,  김영주 ,  강기성 ,  한임호 ,  김태정

IPC: A61K31/26 ,  A61K31/404

CPC classification number: A61K31/404 ,  A61K31/26 ,  A61K31/341 ,  A61K31/381

Abstract: 본 명세서는 설포라판 또는 설포라판 유도체를 포함하는 신독성 감소용 조성물에 관한 것이다. 본 명세서의 설포라판 유도체는 R
1 -(CH
2 )
n -NCS 또는

Abstract translation: 本说明书涉及包含萝卜硫素或萝卜硫素衍生物的用于降低肾毒性的组合物。 本发明的萝卜硫素衍生物可以具有R_1-（CH 2）n-NCS的结构或其相同的结构。 萝卜硫烷或萝卜硫素衍生物具有异硫氰酸的化学结构。 根据本发明，该组合物可保护由肾毒性引起的肾细胞损伤，并减少肾毒性，从而保护肾脏。 因此，该组合物显示出预防或治疗药物肾脏疾病的效果。

公开(公告)号：KR1020140137955A

公开(公告)日：2014-12-03

申请号：KR1020130059268

申请日：2013-05-24

Applicant: 한국과학기술연구원

Inventor： 강기성 ,  함정엽 ,  권학철 ,  김영주 ,  최필주 ,  정봉철

IPC: A61K36/258 ,  A61K31/70

CPC classification number: A61K31/704 ,  A23L33/105 ,  A61K36/258 ,  A61K41/00 ,  A61K2236/333

Abstract: 본 발명은 파낙스속 식물 또는 그 추출물을 아미노산, 초산 또는 그 조합의 존재하에서 마이크로웨이브 조사하여 얻어진 진세노사이드 Rb1, Rc, Rb2, Rd, Rg3, Rk1, Rg5, Rs3, Rs4 및 Rs5의 중량에 대하여 Rs3, Rs4 및 Rs5가 10%이상 함유된 파낙스속 식물 추출물, 그 추출물을 포함하는 약학 조성물 또는 건강기능식품용 조성물, 또는 진세노사이드 Rg3, Rk1 및 Rg5의 함량이 증가된 파낙스속 식물 추출물의 제조방법을 제공한다.

Abstract translation: 提供的是Panax spp。 基于通过微波辐射Panax spp获得的人参皂苷Rb1，Rc，Rb2，Rd，Rg3，Rk1，Rg5，Rs3，Rs4和Rs5的重量，含有Rs3，Rs4和Rs5的植物提取物大于或等于10％。 植物或其提取物在氨基酸，乙酸或其组合的存在下进行; 包含所述提取物的药物组合物或健康功能食品组合物; 或生产Panax spp的方法。 人参皂苷Rg3，Rk1和Rg5含量增加的植物提取物。

公开(公告)号：KR1020140046565A

公开(公告)日：2014-04-21

申请号：KR1020120110713

申请日：2012-10-05

Applicant: 한국과학기술연구원

Inventor： 김수남 ,  이우정 ,  강기성 ,  함정엽 ,  정유정 ,  전영식 ,  신문관

IPC: A61K36/48 ,  A61P13/12

CPC classification number: A23L33/105 ,  A23V2002/00 ,  A23V2200/30 ,  A61K31/045 ,  A61K31/352 ,  A61K36/48

Abstract: The present invention relates to a composition comprising an Amorpha fruticosa extract as an active ingredient for preventing or treating a renal disease. The composition according to the present invention has few side effects when applied to a human body and low possibility to generate resistance caused by long-term use by comprising natural products obtained from the nature as active ingredients. In particular, the composition of the present invention has superior efficacy for protecting kidney cells, thereby the composition can be valuably used for preventing or treating the renal disease. [Reference numerals] (AA) Cell survival rate; (BB) Concentration; (CC) Example (3-1) ug/ml; (DD) Example (4) uM; (EE) Example (3) uM

Abstract translation: 本发明涉及一种组合物，其包含作为预防或治疗肾脏疾病的活性成分的阿魏糖提取物。 当应用于人体时，根据本发明的组合物具有很少的副作用，并且通过将由天然产物获得的天然产物作为活性成分，产生由长期使用引起的耐药性的可能性低。 特别地，本发明的组合物具有优异的保护肾细胞的功效，因此可有效地用于预防或治疗肾脏疾病。 （附图标记）（AA）细胞存活率; （BB）浓度; （CC）实施例（3-1）ug / ml; （DD）实施例（4）uM; （EE）实施例（3）uM

公开(公告)号：KR1020140030721A

公开(公告)日：2014-03-12

申请号：KR1020120097228

申请日：2012-09-03

Applicant: 한국과학기술연구원

Inventor： 김수남 ,  이우정 ,  함정엽 ,  권학철 ,  정봉철

IPC: A61K36/48 ,  A61K31/351 ,  A61K31/35 ,  A61P3/04

CPC classification number: A61K36/48 ,  A23L33/105 ,  A61K31/05 ,  A61K31/353

Abstract: The present invention relates to a composition comprising an Amorpha fruticosa extract for PTP inhibition and PPAR activation. The composition of the present invention is capable of reducing blood glucose by increasing susceptibility to insulin as both of activation and expression of PTP1B are inhibited, and shows an outstanding activity for glucose uptake in muscle cells. [Reference numerals] (AA) Normal condition; (BB,FF,II,KK) Control group; (CC,GG) Example ; (DD,HH) Example ; (EE) Insulin resistance condition; (JJ,LL) Example

Abstract translation: 本发明涉及一种组合物，其包含用于PTP抑制和PPAR活化的弗氏酵母提取物。 本发明的组合物能够通过增加对胰岛素的敏感性而降低血糖，因为PTP1B的活化和表达都被抑制，并且对于肌肉细胞中的葡萄糖摄取显示出突出的活性。 （附图标记）（AA）正常条件; （BB，FF，II，KK）对照组; （CC，GG）实施例<3-1>; （DD，HH）实施例<5>; （EE）胰岛素抵抗状况; （JJ，LL）实施例<6>

公开(公告)号：KR101334887B1

公开(公告)日：2013-11-29

申请号：KR1020110112394

申请日：2011-10-31

Applicant: 한국과학기술연구원

Inventor： 양현옥 ,  권학철 ,  김준기 ,  차진욱 ,  김영주 ,  함정엽

IPC: A61K36/48 ,  A61P25/32 ,  A61P1/08 ,  A61P1/00

CPC classification number: A61K36/489 ,  A23L33/105 ,  A23V2002/00 ,  A61K2236/30 ,  A23V2200/334 ,  A23V2250/21

Abstract: 고삼 (
Sophora

flavescens ) 추출물을 유효성분으로 포함하는 알코올성 숙취 예방 또는 숙취 해소용 약학 조성물; 고삼 (
Sophora

flavescens ) 추출물을 포함하는 숙취 해소용 식품 조성물; 및 알코올 대사 활성화 작용이 우수한 고삼 추출물의 분획물의 제조 방법이 제공된다.

公开(公告)号：KR1020130125746A

公开(公告)日：2013-11-19

申请号：KR1020130136547

申请日：2013-11-11

Applicant: 한국과학기술연구원

Inventor： 강기성 ,  김수남 ,  함정엽 ,  이우정 ,  야마베노리꼬 ,  이지환

IPC: A61K31/70 ,  A61K36/258 ,  A61P35/00 ,  A61P13/12

Abstract: Provided is a composition for preventing, relieving or treating renal diseases, comprising Maillard browning reaction products as active ingredients wherein the products are acquired by reacting Ginsenoside Re, Panax genus plant extract including Ginsenoside Re, or glucose with an amino acid at 100-130 for 0.5-12 hours. [Reference numerals] (AA) Ginsenoside Re;(BB) Ginsenoside Rg_2;(CC) dehydration;(DD) Ginsenoside Rg_6;(EE) Ginsenoside F_4;(FF) Separated glucose + glycine;(GG) Maillard-type browning reaction

Abstract translation: 提供了用于预防，缓解或治疗肾脏疾病的组合物，其包含美拉德褐变反应产物作为活性成分，其中通过人参皂甙Re，Panax属植物提取物（包括人参皂甙Re）或葡萄糖与100-130的氨基酸反应获得产物 0.5-12小时。 （AA）人参皂甙Re;（BB）人参皂苷Rg_2;（CC）脱水;（DD）人参皂甙Rg_6;（EE）人参皂甙F_4;（FF）分离葡萄糖+甘氨酸;（GG）美拉德型褐变反应

公开(公告)号：KR1020130109495A

公开(公告)日：2013-10-08

申请号：KR1020120031250

申请日：2012-03-27

Applicant: 한국과학기술연구원

Inventor： 김수남 ,  강기성 ,  이우정 ,  정유정 ,  전영식 ,  이지환 ,  황예란 ,  함정엽

IPC: A61K36/8984 ,  A61P13/12

CPC classification number: A61K36/8984 ,  A23L33/105 ,  A23V2002/00 ,  A23V2200/30

Abstract: PURPOSE: A composition containing Dendrobium moniliforme for preventing or treating renal diseases is provided to lessen side effects when the composition is applied to human body and to show less resistance even after long-term use. CONSTITUTION: A composition for preventing or treating renal diseases contains 0.001-10 wt% of a Dendrobium moniliforme extract as an active ingredient. The extract is a C1-C6 alcohol extract of Dendrobium moniliforme. C1-C6 alcohol is methanol or ethanol. The composition is used for reducing serum creatinine. [Reference numerals] (AA) Sell survival rate (%); (BB) Dendrobium monile

Abstract translation: 目的：提供一种用于预防或治疗肾脏疾病的含有石斛石斛的组合物，用于减轻组合物施用于人体时的副作用，即使长期使用后也显示出较低的抗性。 构成：用于预防或治疗肾脏疾病的组合物含有0.001-10重量％的石斛提取物作为活性成分。 提取物是石斛石斛的C1-C6醇提取物。 C1-C6醇是甲醇或乙醇。 该组合物用于降低血清肌酐。 （附图标记）（AA）销售存活率（％）; （BB）石斛石斛

公开(公告)号：KR1020130093331A

公开(公告)日：2013-08-22

申请号：KR1020120014831

申请日：2012-02-14

Applicant: 한국과학기술연구원

Inventor： 강기성 ,  함정엽 ,  김수남 ,  권학철 ,  정봉철 ,  이우정 ,  박순혜

IPC: A61K36/258 ,  A61K31/704 ,  A61P35/00

CPC classification number: A61K36/258 ,  A23L33/105 ,  A23L33/175 ,  A61K31/198 ,  A61K31/704 ,  A61K2236/333

Abstract: PURPOSE: A processed ginseng extract is provided to contain a large amount of ginsenoside Rg3, Rg5, Rk1, and to selectively contain ginsenoside of 20 (S)-Rg3 or ginsenoside of 20 (R)-Rg3 depending on the desired effect. CONSTITUTION: A processed panax species plant extract is obtained by Maillard-browning a panax species plant extract with more than one amino acid selected from a group comprising arginine, alanine, and valine at 100-130 deg. C for 0.5-12 hours. The processed panax species plant extract is obtained by Maillard-browing the panax species plant extract with more than one amino acid selected from a group comprising leucine and glutamine at 100-130 deg. C for 0.5-12 hours. A pharmaceutical composition for anti-cancer, neuroprotection, inhibition of platelet aggregating, anti-oxidation, anti-inflammation, kidney protection, and anti-fatigue comprises the panax species plant extract.

Abstract translation: 目的：提供加工的人参提取物以含有大量人参皂苷Rg3，Rg5，Rk1，并根据所需效果选择性地含有20（S）-Rg3或人参皂苷20（R）-Rg3的人参皂甙。 构成：在100-130度下，通过美拉德褐化具有多于一种氨基酸的选自精氨酸，丙氨酸和缬氨酸的氨基酸，获得经处理的藜属植物提取物。 C为0.5-12小时。 经加工的ax属植物提取物通过美拉德在100-130度下从含有亮氨酸和谷氨酰胺的组中选出的多于一种氨基酸的堇菜属植物提取物获得。 C为0.5-12小时。 用于抗癌，神经保护，抑制血小板聚集，抗氧化，抗炎，肾脏保护和抗疲劳的药物组合物包括豌豆种植物提取物。

公开(公告)号：KR1020130047458A

公开(公告)日：2013-05-08

申请号：KR1020110112506

申请日：2011-10-31

Applicant: 한국과학기술연구원

Inventor： 김수남 ,  이우정 ,  함정엽 ,  정유정 ,  황예란 ,  전영식 ,  윤구

IPC: A61K36/8984 ,  A61K31/045 ,  A61K31/047 ,  A61P3/04

CPC classification number: A61K36/8984 ,  A61K31/047 ,  A61K31/09 ,  A61K2236/333 ,  Y10S514/866 ,  Y10S514/909

Abstract: PURPOSE: A composition containing Dendrobium moniliforme is provided to prevent, relieve, or treat PPAR activation regulation-related diseases including obesity, metabolic diseases, and cardiovascular diseases. CONSTITUTION: A composition for preventing or treating PPAR activation regulation-related diseases contains Dendrobium moniliforme as an active ingredient. A composition for health functional food for preventing or treating PPAR activation regulation-related diseases contains Dendrobium moniliforme as an active ingredient. Dendrobium moniliforme is used as pulverized Dendrobium moniliforme, a dried material thereof, or a crude extract prepared by using a solvent which is selected from water, C1-C4 alcohol, and a combination thereof. The C1-C4 alcohol is methanol or ethanol. Dendrobium moniliforme is also used as a fraction which is prepared from the crude extract using n-hexane, methylene chloride, or ethyl acetate. [Reference numerals] (AA) Relative value(%); (BB) No treatment group, Troglitazone; (CC) Example ; (DD) Example ; (EE) Example n-Hx; (FF) Example MC; (GG) Example EA; (HH) Example fr2; (II) Example fr3; (JJ) Example fr2-2; (KK) Example fr2-5; (LL) Example compound 1; (MM) Example compound 2; (NN) Example compound 3; (OO) Example compound 4

Abstract translation: 目的：提供含有石斛仁的组合物，以预防，缓解或治疗PPAR活化调节相关疾病，包括肥胖，代谢疾病和心血管疾病。 构成：用于预防或治疗PPAR活化调节相关疾病的组合物含有石斛石斛作为活性成分。 用于预防或治疗PPAR活化调节相关疾病的健康功能性食品的组合物含有石斛兰作为活性成分。 石斛石斛被用作粉状石斛，其干燥物，或使用选自水，C1-C4醇及其组合的溶剂制备的粗提取物。 C1-C4醇是甲醇或乙醇。 石斛也用作由粗提取物使用正己烷，二氯甲烷或乙酸乙酯制备的级分。 （附图标记）（AA）相对值（％）; （BB）无治疗组，曲格列酮; （CC）实施例<1-1>; （DD）实施例<1-2>; （EE）实施例<2> n-Hx; （FF）实施例<2> MC; （GG）实施例 EA; （HH）实施例<3> fr2; （II）实施例<3> fr3; （JJ）实施例<3> fr2-2; （KK）实施例<3> fr2-5; （LL）实施例<3>化合物1; （MM）实施例3化合物2; （NN）实施例3化合物3; （OO）实例<3>化合物4

公开(公告)号：KR1020100082255A

公开(公告)日：2010-07-16

申请号：KR1020090001660

申请日：2009-01-08

Applicant: 한국과학기술연구원

Inventor： 함정엽 ,  안홍열 ,  양현옥 ,  조영애 ,  김동수

IPC: C07F5/02 ,  C07F1/06

CPC classification number: C07F5/027

Abstract: PURPOSE: A novel potassium haloaryltrifluoroborate derivative compound and a method for preparing the same are provided to use in manufacturing medicine and various organic synthesis reactions. CONSTITUTION: A potassium haloaryltrifluoroborate derivative compound is denoted by chemical formula 1. A method for preparing the potassium haloaryltrifluoroborate derivative compound comprises: a step of mixing dihaloaryl compound of chemical formula 2 and borate compound of B(-OR_2)_3 in a solvent; and a step of adding lithium compound of R_2Li and potassium hydrogen fluoride. The solvent is diethyl ether(Et_2O), tetrahydrofuran, 1,4-dioxane, pentane, hexane, or heptanes. The borate compound is timethylborate(B(-OCH_3)_3), triethylborate(B(-OCH_2CH_3)_3), tripropylborate(B(-OCH_2CH_2CH_3)_3), or triphenylborate(B(-OPh)_3).

Abstract translation: 目的：提供新的卤代卤代三氟硼酸钾衍生物化合物及其制备方法，用于制备药物和各种有机合成反应。 构成：卤代芳基三氟硼酸钾衍生物化合物由化学式1表示。卤代芳基三氟硼酸钾衍生物化合物的制备方法包括：将化学式2的二卤代芳基化合物与B（-OR_2）3的硼酸酯化合物在溶剂中混合的步骤; 以及添加R_2Li和氟化氢钾的锂化合物的步骤。 溶剂是二乙醚（Et 2 O），四氢呋喃，1,4-二恶烷，戊烷，己烷或庚烷。 硼酸盐化合物是硼酸三乙酯（B（-OCH 3）3），硼酸三乙酯（B（-OCH 2 CH 3）3）），三异丙基硼酸盐（B（-OCH 2 CH 2 CH 3）3））或三苯基硼酸盐（B（-OPh）3））。